Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
12. Oktober 2023 16:05 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology is participating in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25th
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
11. Oktober 2023 08:00 ET
|
Vir Biotechnology, Inc.
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
05. Oktober 2023 16:30 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
03. Oktober 2023 07:59 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
20. September 2023 08:00 ET
|
Vir Biotechnology, Inc.
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
29. August 2023 16:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the...
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
03. August 2023 16:05 ET
|
Vir Biotechnology, Inc.
– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of...
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
26. Juli 2023 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
20. Juli 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
29. Juni 2023 09:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs...